Showing results (161-170 of 171) with videos related to
Sort By:
Pageof 18
Cancer Discovery|October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumorsJanneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.Bioorganic & Medicinal Chemistry Letters|September 8, 2009
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTORKeith A Menear, Sylvie Gomez, Karine Malagu, et al.Proceedings of the National Academy of Sciences of the United States of America|October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymeraseVincent M Loh, Xiao-ling Cockcroft, Krystyna J Dillon, et al.Journal of Medicinal Chemistry|September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1Keith A Menear, Claire Adcock, Robert Boulter, et al.Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.Journal of Medicinal Chemistry|June 20, 1997
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitorsA O Stewart, P A Bhatia, J G Martin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacyHelen M R Robinson, Vera Grinkevich, Jayesh B Majithiya, et al.Pageof 18